Introduction
Methods
Sample population
Data collection
Outcome measure
Statistical analysis
Sensitivity analysis
Results
Measures | Mean ± SD, median [p25 p75], N (%) |
---|---|
Age (in years) | 82.7 ± 5.5 |
Female | 201 (48.1) |
Nb of pts benefiting from social support (n =416) | 244 (58.6) |
Solid Cancer | |
- Dermatological* | 339 (81.1) |
- Digestive | 10 (2.4) |
- Gynecological¥ | 124(29.7) |
- HEENT | 70 (16.8) |
- Pulmonary | 24 (5.7) |
- Urologic | 18 (4.3) |
Hematological Cancer | |
- AML | 79 (18.9) |
- CLL | 1 (0.2) |
- Lymphoma | 34 (7.9) |
- Myelodysplasia | 23 (5.5) |
- Myeloma | 8 (1.9) |
Metastatic solid tumor (n = 179) | |
- Present | 73 (38.8) |
- Absent | 106 (60.1) |
Cancer stage | |
- Stage I | 155 (37.0) |
- Stage II | 75 (17.9) |
- Stage III | 109 (26.0) |
- Stage IV | 79 (18.9) |
G8 score (n=397) | 12 [9.5; 13.5] |
Charlson Comorbidity Index** | 4 [4; 5] |
Patients without Cancer, n = 1578 | Patients with Cancer, n = 418 | Total number of patients, n = 1996 | p | |
---|---|---|---|---|
Age (years) | 82.9 [78.5; 87.0] | 82.8 [79.3; 86.4] | 82.9 [78.7; 86.9] | 0.9 |
Female (N, %) | 1080 (68.4) | 201 (48.0) | 1281 (64.1) | <0.001 |
Marital status (N, %) | 0.01 | |||
Widowed | 713 (45.6) | 161 (38.5) | 874 (44.1) | |
Married | 612 (39.1) | 203 (48.5) | 815 (41.1) | |
Single | 95 (6.0) | 21 (5.0) | 116 (5.8) | |
Divorced | 139 (8.9) | 32 (7.6) | 171 (8.6) | |
Living place (N, %) | 0.001 | |||
Home — alone | 912 (58.5) | 284 (68.2) | 1196 (60.6) | |
Home with partner | 552 (35.4) | 110 (26.4) | 662 (33.5) | |
Assisted living | 46 (2.9) | 6 (1.4) | 52 (2.6) | |
Nursing home | 47 (3.0) | 16 (3.8) | 63 (3.2) | |
Education (N, %) | <0.001 | |||
No education | 69 (4.6) | 30 (7.2) | 99 (5.1) | |
Primary school | 537 (35.7) | 202 (48.6) | 739 (38.5) | |
Middle school | 366 (24.3) | 69 (16.6) | 435 (22.6) | |
High school | 232 (15.4) | 45 (10.8) | 277 (14.4) | |
University | 300 (20.0) | 69 (16.6) | 369 (19.2) | |
Activity of Daily Living (ADL) | 6 [5; 6] | 6 [5; 6] | 6 [5; 6] | 0.7 |
CCI* | 4 [4; 5] | 4 [4; 5] | 4 [4; 5] | <0.001 |
MMSE | 26 [21; 28] | 26 [23; 29] | 26 [22; 29] | 0.1 |
SPPB | 8 [5; 10] | 8 [5; 10] | 8 [5; 10] | 0.4 |
MNA | 25 [22; 27] | 23 [20; 25] | 24.5 [21.5; 26.5] | <0.001 |
Audition HHIE-S** (N, %) | 0.8 | |||
Normal | 835 (52.9) | 224 (53.6) | 1059 (53.0) | |
Mild to moderate hearing loss | 531 (33.6) | 143 (34.2) | 674 | (33.7) |
Severe hearing loss | 212 (13.4) | 51 (12.2) | 263 (13.1) | |
Vision ¥ (N, %) | 0 (0) | 147 (35.1) | 147 (7.3) | <0.001 |
Frailty Index | 0.17 [0.11; 0.26] | 0.19 [0.11; 0.29] | 0.17 [0.11; 0.27] | 0.057 |
Fried phenotype (N, %) | 0.1 | |||
Robust | 149 (9.5) | 33 (7.9) | 181 (9.2) | |
Pre-frail | 632 (40.8) | 155 (37.1) | 787 (40.0) | |
Frail | 766 (49.5) | 229 (54.9) | 995 (50.6) | |
Fried criteria | ||||
Weight loss | 363 (23.1) | 179 (42.8) | 542 (27.3) | <0.001 |
Exhaustion | 759 (49.1) | 214 (51.5) | 973 (49.6) | 0.3 |
Low physical activity | 834 (53.1) | 200 (47.8) | 1034 (52.0) | 0.1 |
Weakness | 741 (52.4) | 180 (53.2) | 921 (52.6) | 0.9 |
Slow gait | 360 (40.2) | 69 (33.9) | 429 (39.0) | 0.1 |
RRR | 95% CI | p | |
Outcome | |||
Frailty Phenotype ** | |||
Pre-Frail* | |||
Cancer | 0.9 | [0.5; 1.6] | 0.9 |
Frail* | |||
Cancer | 1.2 | [0.7; 2.0] | 0.4 |
OR | 95% CI | p | |
Outcome | |||
Fried criteria | |||
Weight Loss¥ | |||
Cancer | 2.3 | [1.7; 3.1] | <0.001 |
Exhaustion¥ | |||
Cancer | 1.06 | [0.8; 1.4] | 0.6 |
Low physical activity¥ | |||
Cancer | 0.8 | [0.6; 1.0] | 0.1 |
Weakness¥ | |||
Cancer | 1.07 | [0.8; 1.4] | 0.6 |
Slow gait¥ | |||
Cancer | 0.8 | [0.5; 1.2] | 0.2 |